Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12000
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.date.accessioned2015-05-16T01:38:09Z
dc.date.available2015-05-16T01:38:09Z
dc.date.issued2014-01-27en
dc.identifier.citationThe Journal of Endocrinology 2014; 220(3): R37-55en
dc.identifier.govdoc24353306en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12000en
dc.description.abstractA wealth of observational studies show that low testosterone is associated with insulin resistance and with an increased risk of diabetes and the metabolic syndrome. Experimental studies have identified potential mechanisms by which low testosterone may lead to insulin resistance. Visceral adipose tissue is an important intermediate in this relationship. Actions of testosterone or its metabolite oestradiol on other tissues such as muscle, liver, bone or the brain, and body composition-independent effects may also play a role. However, definitive evidence from randomised controlled trials (RCTs) to clarify whether the association of low testosterone with disordered glucose metabolism is causative is currently lacking. It therefore remains possible that this association is due to reverse causation, or simply originates by association with common health and lifestyle factors. RCTs of testosterone therapy in men with or without diabetes consistently show modest metabolically favourable changes in body composition. Despite this, testosterone effects on glucose metabolism have been inconsistent. Recent evidence suggests that the hypothalamic-pituitary-testicular axis suppression in the majority of obese men with metabolic disorders is functional, and may be, at least in part, reversible with weight loss. Until further evidence is available, lifestyle measures with emphasis on weight reduction, treatment of comorbidities and optimisation of diabetic control should remain the first-line treatment in these men. Such measures, if successful, may be sufficient to normalise testosterone levels in men with metabolic disorders, who typically have only modest reductions in circulating testosterone levels.en
dc.language.isoenen
dc.subject.otherdiabetesen
dc.subject.otherglucose metabolismen
dc.subject.otherinsulin resistanceen
dc.subject.otherobesityen
dc.subject.othertestosteroneen
dc.subject.otherGlucose.metabolismen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMetabolic Diseases.metabolismen
dc.subject.otherObesity.metabolismen
dc.subject.otherTestosterone.metabolismen
dc.titleTestosterone and glucose metabolism in men: current concepts and controversies.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe Journal of endocrinologyen
dc.identifier.affiliationDepartment of Medicine Austin Health, University of Melbourne, 145 Studley Road, Heidelberg, Victoria 3084, Australia Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1530/JOE-13-0393en
dc.description.pagesR37-55en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/24353306en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.